Saxagliptin: A novel antiparkinsonian approach
Authors:
- Muhammad Y. Al-ShorbagyMAMuhammad Y. Al-Shorbagy
- Hany H. ArabHAHany H. Arab
- Dalaal M. AbdallahDADalaal M. Abdallah
- 1 February 2015
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 89, 308-317
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesisBMC Neuroscience, 2012
- Nitric oxide and DOPAC-induced cell death: From GSH depletion to mitochondrial energy crisisMolecular and Cellular Neuroscience, 2011
- Dual Functionality of Myeloperoxidase in Rotenone-Exposed Brain-Resident Immune CellsThe American Journal of Pathology, 2011
- Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic ratsBritish Journal of Pharmacology, 2011
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismProceedings of the National Academy of Sciences, 2009
- Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's diseaseJournal of Neuroinflammation, 2008
- Role and regulation of ferritin H in rotenone-mediated mitochondrial oxidative stressFree Radical Biology and Medicine, 2008
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profilingBritish Journal of Pharmacology, 2007
- Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson’s diseaseThe AAPS Journal, 2006
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976